Blog

Scientists confirm blood test could track Alzheimer's disease

The protein is called neurofilament light. It spills out of damaged and dying nerve cells, into the cerebrospinal fluid and then travels from there into the bloodstream. Previous studies have already demonstrated that blood levels of neurofilament light are higher in people with diseases, such as Alzheimer's, that destroy nerve cells and tissue in the brain. However, few of these have been long-term investigations. Read the full article HERE

Mapping Route to Recurrence in Breast Cancer Cells

For many women who thought they had beaten breast cancer, the news that it has roared back years later comes as an especially cruel diagnosis with no clear answers for why or how it recurs. Now a team of Duke Cancer Institute researchers has filled in some critically unknown details that could lead to potential strategies to halt the process. Experimenting in mice, the researchers tracked a series of events that enable a small reservoir of treatment-resistant cancer cells to awake from dormancy, grow and spread. The findings appear online in eLife. Read the full article HERE

After the Diagnosis: A Guide to Alzheimer’s Disease

The most common cause of dementia in the U.S., Alzheimer’s disease afflicts an estimated 5.8 million Americans, according to the Alzheimer’s Association, and that number is only projected to grow. A difficult diagnosis for any individual and their loved ones, the progressive brain disorder “slowly destroys memory and thinking skills and eventually, the ability to carry out the simplest tasks,” the National Institute on Aging notes. Read the full article HERE

Study: 23andMe gene test might falsely reassure some people of breast cancer risk

Since 2010, 23andMe has charged people to test themselves for potentially harmful gene mutations, such as those in the BRCA1 and BRCA2 genes, which, when mutated, can dramatically increase a person’s risk for developing breast or ovarian cancer. But while 23andMe can screen for the three most well-known BRCA mutations, the test is not approved by the Food and Drug Administration to test for the remaining 1,000-plus BRCA mutations. This presents a problem: As many as 94 percent of people carrying a BRCA mutation may receive a false-negative if they take the stripped-down test 23andMe offers, according to a recent study. Read the full article HERE

Mayo doctors in La Crosse call breast cancer screening tool an early success

Doctors at Mayo-Franciscan in La Crosse say a new, cutting-edge breast cancer screening tool is already paying major dividends. Mayo is one year into a study of local patients who have received molecular breast imaging, which uses a radioactive tracer and specialized camera to detect breast cancer, and which could increase the rate of detection by more than 250%, doctors say. Read the full article HERE

Eyes reveal early Alzheimer's disease

Scientists detected these vascular changes in the human eye non-invasively, with an infrared camera and without the need for dyes or expensive MRI scanners. The back of the eye is optically accessible to a new type of technology (OCT angiography) that can quantify capillary changes in great detail and with unparalleled resolution, making the eye an ideal mirror for what is going on in the brain. Read the full article HERE

Stony Brook team has breakthrough in 'triple-negative' breast cancer research

Medical scientists have discovered a gene underlying one of the most lethal forms of breast cancer, and at the same time are proposing a way to block its activity, paving the way to successful treatment for a type of cancer that is tough to treat. Lori Chan and her team at Stony Brook University have been studying a form of breast cancer known as “triple negative,” a designation that means three key markers are missing on tumor cells. These markers are the targets of medications that are used to successfully treat other forms of the disease, boosting patients' survival. Read the full article HERE

Northwestern to Study New Alzheimer’s Disease Drug

More than 5 million Americans are living with Alzheimer’s disease, including 230,000 in Illinois. By 2050, that number is projected to rise to nearly 14 million Americans, according to the Alzheimer’s Association. There is no cure for the neurodegenerative condition, symptoms of which include memory loss, difficulty completing daily tasks and challenges in planning or solving problems. Many clinical trials are focused on prevention or disease-modifying therapies, which tend to exclude people who are already experiencing symptoms, says Northwestern University neurologist Dr. Ian Grant. While those types of therapies could eventually lead to a cure, Grant says it’s also important to study ther

Featured Posts
Recent Posts
Archive
Search By Tags
RSS Feed
  • Facebook - White Circle
  • Twitter - White Circle
  • Instagram - White Circle
  • LinkedIn - White Circle

Connect with us on social media

© 2020 Care For A Cure, Inc. is a non-profit organization

with a 501(c)(3) tax exempt status. All rights reserved.